Cbd oil for central sensitization

CBD Oil from Hemp, a Powerful New Tool for Pain Relief!

One third of Americans needlessly suffer with pain. 15,000 die every year from overdose of prescription narcotics. Another 30,000-50,000 die avoidable deaths from arthritis medications (like ibuprofen).

Meanwhile, having failed miserably at its battle against pain, the government has now seemingly declared war on the people in pain. This is horrible and abusive, adds social stigma to people’s suffering, and causes much more toxicity than benefit. Attacking people in pain, and denying them the treatment they need, is inexcusable!

Although I hesitate to jump into this political quagmire, we’ve had such incredible feedback from people getting relief from a powerful new natural tool for pain relief that I can’t help but add my opinion — and you don’t have to wait for your physician to catch up to the research. I’m talking about cannabidiol (or CBD), a therapeutic compound found in hemp oil and marijuana! And, with hemp oil now being available, you don’t have to get high, or take the risk of getting arrested, to use them!

Let’s start with one clear and simple truth: Pain is more toxic than pain medications! Yet many are given a Sophie’s Choice; Be in pain, or die from pain medication — a ridiculous choice to be offered.

All too many doctors default to choice one, be in pain. The good news? There’s a “door number three” available!

Treating the Root Causes of Pain with the Fibromyalgia Model

First, recognize that pain is not your enemy. Rather, it’s the oil light on your body’s dashboard telling you that something needs attention. You wouldn’t put a Band-Aid on the light or surgically remove it right? You’d add oil. That’s the sensible “third door” in dealing with pain. Give your body what is asking for, and the pain often goes away.

In our study using the S.H.I.N.E.® Protocol, 91% of fibromyalgia patients improved with an average 90% increase in quality of life. This success rate results because S.H.I.N.E. works to identify the underlying sources of pain, and then gives your body what it’s asking for. This makes fibromyalgia an excellent model for pain management, as it addresses most of the key biochemical components of pain listed below.

  • Inadequate energy in muscles and nerves
  • Inflammation
  • Nerve pain from other causes
  • Central sensitization or “brain pain”
  • Neurotransmitters (e.g., NMDA)

In fibromyalgia, these underlying sources of pain often exacerbate into creating combinations of multiple health issues, including:

  • Insomnia
  • Anxiety and depression
  • Adrenal fatigue
  • Low testosterone

Hemp Oil, a New Addition to My Favorite Herbal Pain Toolkit

Amazingly, all of the kinds of pain listed above can be successfully addressed, naturally, using cannabinoids such as hemp oil or other CBDs! Let’s look at some of the active components of marijuana and hemp oil, as well as some of the observations made in various studies.

THC (Only in Marijuana, Not Hemp Oil)

THC is the most talked about component in marijuana, as it’s what causes the psychoactive high. Yet it can also be helpful, even if it does come with significant side effects, such as poor functioning and possibly jail time. But despite this, it’s still safer than arthritis medications and narcotics.

  • CBD has been the most actively researched.
  • Other components of the herb, as usual, significantly add to the synergy.
  • Provides antioxidative, anti-inflammatory, and neuroprotection effects.
  • Reduces joint swelling, even helpful in rheumatoid arthritis.
  • Shows no drop-off in benefits due to increasing tolerance (i.e., it maintains its effectiveness over time).
  • Decreases “aversive conditioned memory” (fear and suffering).
  • Potently reduces anxiety or fear.
  • North American forms of marijuana are low in CBD.
See also  Is cbd oil good for interstitial cystitis

The Science Speaks for Itself

Below are excerpts from various CBD and THC studies and reviews that reveal the benefits of hemp oil:

  • “Cannabis use improved symptoms such as spasticity, pain, tremor and depression in more than 90% of patients. In eight different clinical studies, MS patients have also reported the benefits of THC.”
  • “Arevalo-Martin et al. demonstrated that cannabinoid agonists … inhibited the activation of microglial cells.” Translation? It helps central sensitization or brain pain from chronic pain. This is a powerful benefit.
  • CBD, in animal studies, show “anti-inflammatory properties … in rheumatoid arthritis.”
  • A mix of THC and CBD (about 2 ½ mg of each per dose) “was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for … central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain.”
  • “Active in nociceptive spinal areas including mechanisms of wind-up and N-methyl-D-aspartate (NMDA) receptors. It was recently demonstrated that cannabinoid agonists suppress … allodynia. [This helps] neuropathic pain … migraine and fibromyalgia via NMDA mechanisms … [producing a] 30%–40% reduction in NMDA responses.”

On THC and opiates:

  • “THC has been shown to stimulate beta-endorphin production …[and] may allow opiate sparing.” This means it makes opiates more effective at lower dose and may reverse tolerance.
  • A recent JAMA study showed a 15.6% drop in opioid deaths in medical marijuana states after marijuana was legalized, after decades of opioid overdose deaths accelerating.

On cannabinoids and inflammation:

  • “THC has twenty times the anti-inflammatory potency of aspirin and twice that of hydrocortisone, but in contrast to all nonsteroidal anti-inflammatory drugs (NSAIDs), demonstrates no cyclo-oxygenase (COX) inhibition at physiological concentrations.”
  • “Cannabichromene (CBC) is the third most prevalent cannabinoid in cannabis, and is also anti-inflammatory and analgesic.”
  • “Cannabigerol (CBG) exhibits GABA uptake inhibition to a greater extent than THC or CBD, suggesting possible utilization as a muscle relaxant in spasticity. Furthermore, CBG has more potent analgesic… activity than THC.”
  • Hemp terpenoids are also important:
    • “Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone, suggesting an opioid-like mechanism. It also blocks inflammation via PGE-2.”
    • “The cannabis sesquiterpenoid β-caryophyllene is anti-inflammatory … but simultaneously acts as a gastric cytoprotective.”
    • “α-Pinene also inhibits PGE-1, while linalool displays local anesthetic effects.”

    The Benefits of Whole Hemp Oil

    Using the synergy that comes from the multiple components of hemp oil helps all of the components of pain. Instead of side effects from medications, it offers side benefits. These include:

    • Calming
    • Anti-inflammatory
    • Decreases nausea
    • Decreases depression
    • Optimizing Immunity (many studies show the components of hemp oil essentially “tell” cancer cells to self-destruct).

    Sleep, Another Key Side Benefit of Hemp Oil

    • “Highly statistically significant improvements have been observed in sleep parameters in virtually all RCTs performed with [hemp oil components] … in chronic pain conditions leading to reduced symptomatic insomnia due to symptom reduction rather than sedative effects.” Sleep is critical for pain relief, triggering growth hormone release and tissue healing. Cannabinoids are also suggested to decrease sleep apnea.


    The components of hemp oil have been shown to help almost all of the components and types of pain, including:

    • Muscle tightness
    • Nerve pain
    • Inflammation
    • Neurotransmitters including NMDA, GABA, and serotonin
    • Central sensitization
    • Arthritis and even
    • Cancer pain


    Benefits of hemp oil are obtained from a wide range of dosing. Even 1,500 mg a day in children with epilepsy has been shown to be beneficial and safe.

    For pain, I recommend 10-25 mg of CBD up to three times a day, with up to 50 mg at bedtime. This can be combined with other pain medications, and the dose adjusted as works best for you.

    Getting the Right Type of Hemp Oil

    This is important. Without experience, it’s hard to tell how much of the active components are present in many products. Many of them have labels that dramatically misrepresent their content. For example, I’ve seen products with “CBD” in bold type on the label with a content listed at 100 mg, yet provide less than 3 mg per dose.

    A good form comes from Concentrated European Hemp (Cannabis sativa) stalk and seed oil. These can be found in 50 mg capsules of an excellent product called Hemp Oil (by EuroPharma), which contains 20% CBD (i.e., 10 mg of CBD per capsule). This is the hemp oil product I recommend, and it is superb.

    Ignore the politics and go with the science. You Can Get Pain-Free — NOW!

    Review Articles and Study References

      , Cannabis Cannabinoid Res. 2017; 2(1): 139–154. , Neurotherapeutics . 2015 Oct; 12(4): 825–836. , Future Med Chem . Author manuscript; available in PMC 2010 Aug 1. , Ther Clin Risk Manag. 2008 Feb; 4(1): 245–259. , Rambam Maimonides Med J . 2013 Oct; 4(4): e0022.

    Jacob Teitelbaum, M.D. is one of the world’s leading integrative medical authorities on fibromyalgia and chronic fatigue. He is the lead author of eight research studies on their effective treatments, and has published numerous health & wellness books, including the bestseller on fibromyalgia From Fatigued to Fantastic! and The Fatigue and Fibromyalgia Solution. Dr. Teitelbaum is one of the most frequently quoted fibromyalgia experts in the world and appears often as a guest on news and talk shows nationwide including Good Morning America, The Dr. Oz Show, Oprah & Friends, CNN, and Fox News Health.

    Cannabinoids Don’t Relieve Pain So Much as Boost Tolerance

    Cannabinoids appear to help people handle more pain but don’t reduce pain intensity, according to a meta-analysis of experimental human studies.

    Across 18 placebo-controlled studies, cannabinoids increased pain thresholds (Hedges g 0.186, 95% CI 0.054-0.318, P=0.006), but did not reduce the intensity of pain already felt by participants (g 0.017, 95% CI −0.120 to 0.154, P=0.81), according to Martin De Vita, MS, of Syracuse University in New York, and colleagues.

    Instead, cannabinoids appear to make pain feel less unpleasant (g 0.288, 95% CI 0.104-0.472, P=0.002) and more tolerable ( g 0.225, 95% CI 0.015-0.436, P = 0.04), which implies cannabinoids are influencing the affective component of pain rather than the sensory aspect, the authors wrote in JAMA Psychiatry. (Hedges g values indicate effect sizes on a standardized scale, “with 0.20 corresponding to small size, 0.50 corresponding to medium size, and 0.80 corresponding to large size,” the authors explained.)

    “If you think of pain as a noxious sound coming from a radio, the volume is the intensity of that pain,” De Vita told MedPage Today. “After using cannabinoid drugs, it may not decrease the volume of the noxious noise, but it may tune it to a station that’s a little less unpleasant. It won’t be the most beautiful music you’ve ever heard — it will still be pain — but it will be a little less unpleasant.”

    The group’s study sought to consolidate data from a growing body of research examining the role of cannabinoids in pain management. Despite cannabis having been legalized for pain management treatment in many U.S. states, some previous studies found little solid evidence that cannabinoids are effective in treating pain. In general, there are numerous confounding factors — such as dosage and type of cannabinoid administered, as well as patient characteristics like sex — that can influence results.

    De Vita told MedPage Today that most previous studies have examined patients with chronic pain, which often occurs alongside depression, anxiety, or other conditions that could influence the effectiveness of cannabinoid treatment.

    “When you’re looking at [cannabinoid treatment] in healthy patients, you’re going back to those basic pain processes that should be functioning and seeing how cannabinoids actually work on those processes without those additional factors,” he said.

    Taking data from PubMed, EMBASE, MEDLINE, PsycINFO, and CINAHL databases, De Vita and colleagues identified 26 full-text articles, excluding eight because they included participants with chronic pain. Studies were restricted to those enrolling generally healthy individuals who were subjected to standardized pain stimuli in laboratory settings.

    The authors took several measures to ensure accurate effect sizes, including pooling effect sizes when studies used multiple pain-induction methods; treating each cannabinoid type tested as an individual comparison; and extracting “peak effects” from studies that measured pain after cannabis was administered.

    Quality and validity scores were high across measures of pain threshold, tolerance, intensity, and unpleasantness, as well as across mechanical hyperalgesia (average: 9.8 out of 12), with 17 studies (94%) using randomization and 16 (89%) using blinding techniques.

    Just over half of study participants were male. Among those studies reporting a mean age for participants (some did not), the average was 27.

    The reports examined were conducted in the United States, Canada, and Europe from 1974 to 2016. Six studies administered plant-based cannabis (33%), while others administered different forms of synthetic tetrahydrocannabinol (THC), cannabis extract, or synthetic cannabinoids.

    Reduced mechanical hyperalgesia, which reflects central sensitization, was not associated with the intake of cannabinoids (g 0.093, 95% CI −0.059 to 0.244, P=0.23) across all studies.

    In their analysis of pain threshold, researchers found that relatively high cannabinoid dosages were associated with improved pain management, whereas low doses were not (g 0.334 versus g -0.023; PP=0.77).

    The association was also stronger between reduced unpleasantness and cannabinoid administration when participants were given plant-based cannabis (g 0.499, P<0.001), as opposed to synthetic THC substances (g 0.298, P=0.10). The administration of plant-based cannabis (g 0.471, P<0.001) and dronabinol (g 0.313, P=0.002) were both associated with improved pain tolerance as well.

    The composition of males and females in the studies did not significantly affect the study’s results (P>0.05).

    Further research needs to be conducted in order to determine neuropathic pain data and specifically test which forms of cannabinoid treatment, at which doses, and in which populations, are most effective, De Vita said. He also encouraged future studies that administer non-psychoactive cannabinoids, such as cannabidiol, to reduce bias.

    The authors cited the psychoactive nature of cannabinoids as a study limitation, since participants “feel high” when given the active treatment and thus blinding can be comprised. Additionally, the data only recorded static pain measurements and did not assess patient pain across a period of time. For some studies examined, the data was collected at “peak effect” points, which may mean the results were underestimated. The type and dose of cannabinoids distributed across participants also differed, which limits this study’s generalizability.

    “Everyone is saying we need more research and that we need to catch up,” De Vita said. “This is a first step in doing that, starting from the fundamentals of how cannabinoids affect basic pain processes, and now we need to determine some of these follow-up questions.”

    Elizabeth Hlavinka covers clinical news, features, and investigative pieces for MedPage Today. She also produces episodes for the Anamnesis podcast. Follow

    This study was funded by the Syracuse University STEM Fellowship and grants from the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse.

    See also  Cbd oil for dogs nashville tn